Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRS3 | P32247 | 3/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 13/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 13/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 13/20 | 0.43 |
| ▸ | CYP2E1 | P05181 | 12/20 | 0.43 |
| ▸ | CYP2C8 | P10632 | 12/20 | 0.43 |
| ▸ | CYP2B6 | P20813 | 12/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 12/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 11/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | NOS2 | P35228 | 2/20 | 0.41 |
| ▸ | NOS3 | P29474 | 1/20 | 0.41 |
| ▸ | NOS1 | P29475 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1717500 | 0.94 | BRS3 (0.66) | BRS3CYP2D6CYP2C9CYP2C19CYP2E1 | |
| Ufiprazole SCHEMBL3186458 | 0.89 | BRS3 (0.71) | BRS3CYP2D6CYP2C9CYP2C19CYP2E1 | |
| Ufiprazole SCHEMBL3180530 | 0.88 | BRS3 (0.76) | BRS3CYP2D6CYP2C9CYP2C19CYP2E1 | |
| Ufiprazole SCHEMBL3170203 | 0.87 | BRS3 (0.74) | BRS3CYP2D6CYP2C9CYP2C19CYP2E1 | |
| SCHEMBL13068890 | 0.84 | BRS3 (0.70) | BRS3CYP2D6CYP2C9CYP2C19CYP2E1 | |
| SCHEMBL13645483 | 0.84 | BRS3 (0.54) | BRS3CYP2D6CYP2C9CYP2C19CYP2E1 | |
| Ufiprazole SCHEMBL662986 | 0.82 | BRS3 (0.84) | BRS3CYP2D6CYP2C9CYP2C19CYP2E1 | |
| Ufiprazole SCHEMBL29455226 | 0.82 | BRS3 (0.84) | BRS3CYP2D6CYP2C9CYP2C19CYP2E1 | |
| SCHEMBL31097368 | 0.81 | BRS3 (0.66) | BRS3CYP2D6CYP2C9CYP2C19CYP2E1 | |
| SCHEMBL7851921 | 0.81 | BRS3 (0.66) | BRS3CYP2D6CYP2C9CYP2C19CYP2E1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080146610-A1 | 2-Pyridinyl)methylsulfinyl]-1H-benzimidazole derivatives; substituents include methoxy and difluoromethoxy; at least one alkyl hydrogen is replaced by a deuterium atom: 5-difluoromethoxy-2-[(3-methoxy-4-monodeuteriomethoxy)-2-pyridinyl)methylsulfinyl]-1H-benzimidazole; gastrointestinal disorders | NYCOMED GMBH (DE) | 2008-06-19 | — | — | US | claimed |
| US-20100022779-A1 | Isotopically substituted proton pump inhibitors | NYCOMED GMBH (DE) | 2010-01-28 | — | — | US | disclosed |
| US-20100010047-A1 | Isotopically substituted proton pump inhibitors | TAKEDA GMBH (DE) | 2010-01-14 | — | — | US | disclosed |
| US-7601737-B2 | 2-Pyridinyl)methylsulfinyl]-1H-benzimidazole derivatives; substituents include methoxy and difluoromethoxy; at least one alkyl hydrogen is replaced by a deuterium atom: 5-difluoromethoxy-2-[(3-methoxy-4-monodeuteriomethoxy)-2-pyridinyl)methylsulfinyl]-1H-benzimidazole; gastrointestinal disorders | NYCOMED GMBH (DE) | 2009-10-13 | — | — | US | disclosed |
| US-20080146610-A1 | 2-Pyridinyl)methylsulfinyl]-1H-benzimidazole derivatives; substituents include methoxy and difluoromethoxy; at least one alkyl hydrogen is replaced by a deuterium atom: 5-difluoromethoxy-2-[(3-methoxy-4-monodeuteriomethoxy)-2-pyridinyl)methylsulfinyl]-1H-benzimidazole; gastrointestinal disorders | NYCOMED GMBH (DE) | 2008-06-19 | — | — | US | disclosed |
| EP-1910293-A1 | ISOTOPICALLY SUBSTITUTED PROTON PUMP INHIBITORS | Nycomed GmbH (DE) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007012650-A1 | ISOTOPICALLY SUBSTITUTED PROTON PUMP INHIBITORS | NYCOMED GMBH (DE) | 2007-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022779-A1 | Isotopically substituted proton pump inhibitors | SLC10A2, ABCB11, SLC10A1 | BRS3 218/4885CYP2D6 28/4885CYP2C9 100/4885 |
| US-20080146610-A1 | 2-Pyridinyl)methylsulfinyl]-1H-benzimidazole derivatives; substituents include methoxy and difluoromethoxy; at least one alkyl hydrogen is replaced by a deuterium atom: 5-difluoromethoxy-2-[(3-methoxy-4-monodeuteriomethoxy)-2-pyridinyl)methylsulfinyl]-1H-benzimidazole; gastrointestinal disorders | SLC10A2, CYP2J2, CYP2D6 | BRS3 275/4885CYP2D6 3/4885CYP2C9 81/4885 |
| US-20100010047-A1 | Isotopically substituted proton pump inhibitors | SLC10A2, ABCB11, SLC10A1 | BRS3 218/4885CYP2D6 28/4885CYP2C9 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.